Pharmacologic Doses of Medroxyprogesterone May Cause Bone Loss Through Glucocorticoid Activity: An Hypothesis

@article{Ishida2002PharmacologicDO,
  title={Pharmacologic Doses of Medroxyprogesterone May Cause Bone Loss Through Glucocorticoid Activity: An Hypothesis},
  author={Y. Ishida and J. Heersche},
  journal={Osteoporosis International},
  year={2002},
  volume={13},
  pages={601-605}
}
Abstract: A number of studies suggest that progestagens may have beneficial effects on bone metabolism. C21 Progestin medroxyprogesterone acetate (MPA) is one of the most commonly prescribed progestins for hormone replacement therapy and in gynecologic practice. However, it appears that MPA with significant glucocorticoid (GC) activity may decrease bone density. In this review, we argue that bone loss associated with MPA administration is caused by decreased osteoblast differentiation as a… Expand
Overview on the effects of progestins on bone.
TLDR
From the data there are no indications that the various progestins, used in clinical practice, have either a bone-protective or an oestrogen antagonistic activity. Expand
Medroxyprogesterone acetate in the management of cancer cachexia
TLDR
The anticachectic mechanisms of medroxyprogesterone, beyond its endocrine activity, are described to explain its therapeutic efficacy in the treatment of cachexia. Expand
The effects of hormonal contraceptives on bone turnover markers and bone health
TLDR
The effects of combined and gestagen‐only hormonal contraceptives on bone turnover markers and related effects on bone mineral density and fracture risk in premenopausal women, as documented in the literature until January 2009 are reviewed. Expand
Potency of progestogens used in hormonal therapy: Toward understanding differential actions
TLDR
This review evaluates the usage, meaning and significance of the terms affinity, potency and efficacy in different models systems, with a view to improved understanding of their physiological and pharmacological significance. Expand
Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception
TLDR
The molecular mechanisms of intracellular actions of old (MPA, norethisterone, levonorgestrel, gestodene) vs. new (drospirenone, dienogest, trimegestone) generation progestins, via steroid receptors are reviewed. Expand
Sex steroids and bone: current perspectives.
TLDR
There is sufficient information available to conclude that ovarian steroids play an essential role in skeletal homeostasis and synthetic ligands of the estrogen receptor that can evoke the non-genotrophic but not the genotrophic signal of the receptor may be bone anabolic agents. Expand
Retracted: Effect of progestins with different glucocorticoid activity on bone metabolism
TLDR
Progestins are commonly prescribed for hormone replacement therapy (HRT) and contraception, but the effects of progestins on bone metabolism remain unclear and are often controversial. Expand
Progestagens androgenic action on the bone of male castrated mice.
TLDR
The results indicate that only NETA at the dose used in hormonal therapy for prevention of osteoporosis has a slight protective effect against bone mineral loss in castrated mice. Expand
Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy - a systematic review and meta-analysis of controlled trials with direct randomization
TLDR
Estrogen with an osteoblast P4R-acting progestin (EPT) in these five published RCT provides Level 1 evidence that MPA caused significantly greater annual percent spinal BMD gains than the same dose of ET, have implications for management of vasomotor symptoms and potentially for osteoporosis treatment in menopausal women. Expand
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.
TLDR
Differences in chemical structure, metabolism, pharmacokinetics, affinity, potency, and efficacy via steroid receptors, intracellular action, and biological and clinical effects confirm the absence of a class effect of progestogens. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
The role of progestins in hormone replacement therapy
  • R. Lobo
  • Medicine
  • American journal of obstetrics and gynecology
  • 1992
TLDR
With this approach the difference in mortality rates between women who use unopposed estrogen and women whoUse estrogen-progestin therapy will be minimized and will make the appropriate sequential addition of progestin an option in postmenopausal hormone replacement therapy. Expand
Glucocorticoid‐Induced Osteoporosis: Both In Vivo and In Vitro Concentrations of Glucocorticoids Higher Than Physiological Levels Attenuate Osteoblast Differentiation
  • Y. Ishida, J. Heersche
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1998
TLDR
The diverse and complex effects of GCs on bone metabolism are still incompletely understood, mainly due to differences in experimental outcomes in different systems and culture conditions, which could be a result of species differences, age of the experimental animals used, maturation stage of the cells studied, heterogeneity of osteoblast populations, differences between transformed cells and normal cells, or length and dose of GC treatment used. Expand
Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
  • C. Westhoff
  • Medicine
  • The Journal of reproductive medicine
  • 1996
TLDR
Data regarding depression or mood changes in DMPA users are scanty and do not support a causal relationship between use of this contraceptive and affective disorders. Expand
Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
TLDR
The low-dose combination of Premarin plus Provera was similar in its effect on bone to that ofPremarin alone, suggesting that there may be a synergistic effect of this hormone combination on bone. Expand
Premenopausal bone loss and depot medroxyprogesterone acetate administration
  • S. Mark
  • Medicine
  • International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 1994
TLDR
Women who use depot medroxyprogesterone acetate are in a state of partial estrogen deficiency, which may be associated with increased bone loss. Expand
Bone density in women receiving depot medroxyprogesterone acetate for contraception.
TLDR
Women using DMPA have bone density values intermediate between those of normal premenopausal and postmenopausal controls; thus, the degree of oestrogen deficiency induced by DMPA may have an adverse effect on bone density. Expand
Adrenal steroids as parameters of the bioavailability of MA and MPA.
TLDR
Although the median serum MA levels are double those of MPA, suppression of A, C and D is usually similar, with corresponding estrogen levels, demonstrating a comparable and maximal bioavailability. Expand
The effect of medroxyprogesterone acetate on the pituitary-adrenal axis.
TLDR
MPA has cortisol-like effects and the suppression of adrenal function is probably mediated by a negative feedback action on the hypothalamus or pituitary, and a blunted response to maximal ACTH stimulation was found. Expand
Long-term depot-medroxyprogesterone acetate and bone mineral density.
TLDR
This study provided information that the use of DMPA in a Chinese group for > 5 years in associated with bone loss, and a prospective study is needed to confirm these data, which are different from two case-control studies. Expand
...
1
2
3
4
5
...